AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
7 Department of Hematology, Shanghai Jing'an District Beizhan Hospital, Shanghai, China
8 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
9 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
10 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
11 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
12 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
13 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
14 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine,, Shanghai, China, Shanghai Key Laboratory of Gene Editing and Cell-based Immunotherapy for Hematological Diseases, Ruijin Hospital, Shanghai jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Introduction
Although tyrosine kinase inhibitors have substantially improved outcomes in patients with BCR::ABL1-positive acute lymphoblastic leukemia (BCR::ABL1+ ALL), the prognosis of older patients remains poor. We previously developed a refined risk-stratification system for adults aged <65 years that integrates the IKZF1plus genotype with measurable residual disease (MRD) status at 3 months to distinguish risk groups and guide transplantation decisions. Herein, we evaluated the applicability of this system in newly diagnosed patients aged ≥65 years and assessed its potential to inform subsequent treatment strategies.
Methods
This study included newly diagnosed patients aged ≥65 years with BCR::ABL1-positive ALL and adequate organ function. All patients received flumatinib (600 mg/day) combined with vincristine/prednisone (VP)-based chemotherapy. None underwent allogeneic hematopoietic stem cell transplantation. MRD was monitored using multiparameter flow cytometry with a sensitivity of at least 0.01% and real-time quantitative PCR with a sensitivity of 0.001%. Complete molecular remission (CMR) was defined as the absence of quantifiable BCR::ABL1 transcripatients. IKZF1plus status was determined using multiplex ligation-dependent probe amplification (MLPA). Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events, version 5.0.
Results
Between January 2021 and May 2026, 43 patients with de novo BCR::ABL1+ ALL received flumatinib combined with VP-based chemotherapy. The median age was 69.0 years (range, 65-78), and 53.5% of the patients were female. The median white blood cell count was 50.4×109/L (IQR, 12.8-113.0). The BCR::ABL1 p190 and p210 transcripatients were detected alone in 32 and 3 patients, respectively, whereas 8 patients co-expressed both isoforms. Conventional karyotyping identified additional cytogenetic abnormalities in 33/39 patients. Among the 41 patients with available MLPA results, 15 were classified as IKZF1plus and 26 as non-IKZF1plus.
All 43 patients achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy, with no early deaths during this phase. The rates of MRD flow negativity and CMR were 58.1% (25/43) and 9.5% (4/42) after induction, respectively, increasing to 66.7% (26/39) and 27.0% (10/37) at 3 months. After a median follow-up of 33.4 months (range, 1.7-69.7), the estimated 3-year overall survival (OS) and progression-free survival (PFS) rates among evaluable patients were 47.1% and 43.0%, respectively. The median OS and PFS were 35.9 and 32.7 months, respectively.
Among the 37 patients with available data for refined risk stratification, 15 were classified as high risk (IKZF1plus), 15 as intermediate risk (non-IKZF1plus/MRD+), and 7 as low risk (non-IKZF1plus/MRD-). The low-risk group showed superior survival, with 3-year OS and PFS rates of 100% and 75%, respectively, compared with 38.1% and 33.4% in the intermediate/high-risk groups. Among 41 patients evaluated for ABL1 mutations, 20 (48.8%) harbored at least one mutation. T315I was the most common mutation (70.0%, 14/20), followed by Y253H (45.0%, 9/20), and 10 patients developed multiple mutations sequentially or concurrently. Patients with T315I had significantly poorer outcomes than those without T315I (OS: p=0.002; PFS: p<0.001). Moreover, T315I was more frequent in the high-risk group than in the low-risk group (50.0% vs. 14.3%). Four patients received CAR-T therapy: 3 from the intermediate/high-risk groups and 2 with T315I. During a post-CAR-T follow-up of 14 to 18 months, all 4 patients remained alive and relapse-free.
The safety profile was acceptable, with no deaths attributed to flumatinib. Most AEs were grade 1 or 2. Grade 3 AEs included paroxysmal atrial fibrillation (n = 3), heart failure (n = 1), and cerebral infarction (n = 1), all of which resolved with appropriate management. No grade 3 or 4 pleural effusion, pericardial effusion, pulmonary hypertension, or pancreatitis was observed.
Conclusions
This study further identified a subgroup with favorable survival among newly diagnosed older patients with BCR::ABL1-positive ALL, defined by non-IKZF1plus status and achievement CMR at 3 months. CAR-T therapy may be considered for higher-risk patients or those harboring the T315I mutation to improve clinical outcomes.